EGFR L858R

Clinical trials for EGFR L858R explained in plain language.

Never miss a new study

Get alerted when new EGFR L858R trials appear

Sign up with your email to follow new studies for EGFR L858R, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Completed 1

CRISPR therapy takes on Drug-Resistant lung cancer in liver

Disease control Not yet recruiting

This early-stage trial tests a new gene-editing drug called EDB-102 in 15 people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapy. The drug uses CRISPR technology to target and disable a specific cancer-caus…

Matched conditions: EGFR L858R

Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control

Last updated Jun 27, 2026 11:00 UTC

EGFR L858R

Get alerted when new EGFR L858R trials appear

CRISPR therapy takes on Drug-Resistant lung cancer in liver